Sign In
Buy NVRO
$5.84
+0 (+0%)
At Close: Jul 01, 2025
Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Wednesday, 12'th Feb 2025
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
09:15am, Tuesday, 11'th Feb 2025
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp.
Nevro (NVRO) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 07'th Feb 2025
Nevro (NVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
05:46am, Friday, 07'th Feb 2025
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Nevro Corp. - NVRO
04:10pm, Thursday, 06'th Feb 2025
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securiti
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders
11:14am, Thursday, 06'th Feb 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro sharehold
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders
10:14am, Thursday, 06'th Feb 2025
MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical. Click h
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
09:30am, Thursday, 06'th Feb 2025
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device
Here's Why you Should Add Nevro Stock to Your Portfolio Now
12:01pm, Thursday, 23'rd Jan 2025
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
04:30pm, Tuesday, 21'st Jan 2025
REDWOOD CITY, Calif. , Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa
Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS Demand
01:25pm, Wednesday, 15'th Jan 2025
NVRO's preliminary fourth-quarter revenues showcase decline in worldwide and U.S. revenues.
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results
08:30am, Monday, 13'th Jan 2025
Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif. , Jan. 13, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO),
What Makes Nevro (NVRO) a New Buy Stock
01:01pm, Tuesday, 24'th Dec 2024
Nevro (NVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
04:30pm, Tuesday, 17'th Dec 2024
REDWOOD CITY, Calif. , Dec. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa
